Seres Therapeutics (MCRB)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	76.70 mm	76.70 mm	76.70 mm	76.70 mm	76.70 mm	76.70 mm
Cash burn (monthly)	1.47 mm	8.45 mm	9.72 mm	4.17 mm	11.56 mm	13.10 mm
Cash used (since last report)	7.91 mm	45.47 mm	52.32 mm	22.43 mm	62.21 mm	70.51 mm
Cash remaining	68.79 mm	31.23 mm	24.37 mm	54.27 mm	14.49 mm	6.19 mm
Runway (months of cash)	46.8	3.7	2.5	13.0	1.3	0.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

MCRB institutional ownership history Ownership history

58.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	79	94	-16.0%
Opened positions	12	22	-45.5%
Closed positions	27	28	-3.6%
Increased positions	14	25	-44.0%
Reduced positions	27	25	+8.0%

13F shares	Current	Prev Q	Change
Total value	59.81 bn	49.61 bn	+20.5%
Total shares	101.50 mm	85.45 mm	+18.8%
Total puts	470.80 k	465.70 k	+1.1%
Total calls	304.00 k	118.90 k	+155.7%
Total put/call ratio	1.5	3.9	-60.5%

Largest owners	Shares	Value	Change
Flagship Pioneering	23.12 mm	$21.87 bn	0.0%
FMR	22.86 mm	$21.63 bn	+0.6%
NSRGF Nestlé	21.78 mm	$20.94 mm	NEW
Flagship VentureLabs IV	8.79 mm	$33.66 mm	0.0%
Nestle Health Science US	7.59 mm	$26.58 mm	0.0%
Vanguard	6.06 mm	$5.73 bn	-3.6%
BlackRock	1.76 mm	$1.67 bn	NEW
Geode Capital Management	1.39 mm	$1.31 bn	+22.5%
Susquehanna International	1.19 mm	$1.13 bn	-16.5%
Millennium Management	1.02 mm	$966.87 mm	-42.5%

Largest transactions	Shares	Bought/sold	Change
NSRGF Nestlé	21.78 mm	+21.78 mm	NEW
Tang Capital Management	200.00 k	-2.21 mm	-91.7%
BlackRock	1.76 mm	+1.76 mm	NEW
BLK BlackRock	0.00	-1.76 mm	EXIT
Hudson Bay Capital Management	0.00	-1.00 mm	EXIT
Millennium Management	1.02 mm	-755.64 k	-42.5%
Jane Street	20.87 k	-686.20 k	-97.0%
GS The Goldman Sachs Group, Inc.	14.67 k	-652.28 k	-97.8%
MS Morgan Stanley	802.33 k	+631.24 k	+369.0%
NTRS Northern Trust	218.22 k	-503.54 k	-69.8%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

MCRB insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 Feb 25	Moltke Lisa von	Common Stock	Sell	Dispose S	No	Yes	0.8105	4,416	3.58 k	39,875
18 Feb 25	Thomas DesRosier	Common Stock	Sell	Dispose S	No	Yes	0.8105	4,300	3.49 k	142,456
18 Feb 25	Eric D. Shaff	Common Stock	Sell	Dispose S	No	Yes	0.8105	12,726	10.31 k	192,039
18 Feb 25	Matthew R. Henn	Common Stock	Sell	Dispose S	No	Yes	0.8104	3,953	3.20 k	84,443
18 Feb 25	Teresa L. Young	Common Stock	Sell	Dispose S	No	Yes	0.8102	3,338	2.70 k	97,536
15 Feb 25	Moltke Lisa von	Common Stock	Option exercise	Acquire M	No	No	0	8,907	0.00	44,291
15 Feb 25	Moltke Lisa von	Common Stock	Option exercise	Acquire M	No	No	0	2,969	0.00	35,384
15 Feb 25	Moltke Lisa von	RSU Common Stock	Option exercise	Dispose M	No	No	0	8,907	0.00	26,718
15 Feb 25	Moltke Lisa von	RSU Common Stock	Option exercise	Dispose M	No	No	0	2,969	0.00	23,750
15 Feb 25	Thomas DesRosier	Common Stock	Option exercise	Acquire M	No	No	0	8,907	0.00	146,756

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Seres Advances SER-155 Development with FDA Feedback, Plans Next Clinical Study

3 Mar 25

Seres Therapeutics, Inc. (NASDAQ:MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced that it has received constructive feedback from a Type B Breakthrough Therapy designation engagement

12 Health Care Stocks Moving In Thursday's Pre-Market Session

16 Jan 25

Seres Therapeutics Announced New Translational Biomarker Results For Exploratory Endpoints From Its SER-155 Phase 1b Placebo-controlled Study In Patients Undergoing Allogenic Stem Cell Transplantation

9 Jan 25

Following SER-155 administration, there was a statistically significant decrease in fecal albumin, an established biomarker of epithelial barrier integrity, and a positive impact on biomarkers of systemic inflammation

Press releases

From Benzinga Pro

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

16 Jan 25

CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

9 Jan 25

New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased systemic inflammatory